Among patients with T1DM enrolled in our study, the use of CSII, compared with MDI, resulted in lower levels of HbA1c and FBG, while insulin dose reduction was not significant; moreover, CSII outperformed in increasing TIR, decreasing TAR, and achieving CGM-associated targets of TIR ≥ 70% and TAR < 25%. This evidence concerns the gene INS and type 1 diabetes mellitus.